RXRX Recursion Pharmaceuticals
Price Chart
Executive Summary
Recursion Pharmaceuticals reported Q1 2026 EPS of -$0.21, beating consensus of -$0.26 by 18.3%, while revenue of $6.5M missed the $15.8M estimate by 58.9%. The company reiterated its 2026 cash burn guidance of <$390M and highlighted clinical progress across multiple pipeline programs, but the sharp revenue decline and ongoing losses temper the positive EPS surprise.
Actionable Insight
The EPS beat and improved cash burn are positive, but the 56% revenue decline is a significant red flag. Watch for upcoming REC-4881 regulatory update in 2H26 and additional REC-1245 dose escalation data — these are the key catalysts. The reiterated cash runway into early 2028 provides a long buffer, but revenue trajectory needs to stabilize for sustained bullish sentiment.
Key Facts
- EPS of -$0.21 beat consensus of -$0.26 by 18.3%
- Revenue of $6.5M missed consensus of $15.8M by 58.9%
- Net loss narrowed to $117.5M from $202.5M in Q1 2025
- Cash, cash equivalents and restricted cash: $665.2M as of March 31, 2026
- Reiterated 2026 operational cash burn guidance of <$390M, runway into early 2028
- R&D expenses decreased to $87.9M from $129.6M YoY
- Operating cash flow improved to -$81.1M from -$132.0M YoY
- REC-1245 (RBM39 degrader) showed favorable safety and PK data in Phase 1/2
- REC-4881 (MEK1/2) Phase 2 data showed 43% median polyp burden reduction at Week 13
- First patient dosed in REC-4539 (LSD1 inhibitor) Phase 1 study in April 2026
Financial Impact
Revenue declined 56.1% YoY to $6.5M; net loss improved 42.0% YoY to $117.5M; cash burn reduced 38.6% YoY to $81.1M operating cash outflow
Risk Factors
- Revenue decline of 56% YoY due to completion of Roche project phases
- Heavy reliance on partnership revenue; no product revenue yet
- High cash burn rate despite improvements; $665M cash may not cover all pipeline programs
- Clinical-stage biotech with no approved products; all programs are early-stage
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288617 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $3.10 awaiting T+5 | awaiting T+5 | — | $3.15 (+1.61%) |
|
Jun 5, 2026
7d ago
|
Insider Cluster
| $3.32 awaiting T+5 | awaiting T+5 | — | $3.15 (−4.98%) |
|
May 29, 2026
14d ago
|
Press Release
| $3.79 $3.32 | ▼ −12.53% | ▼ −9.78% | $3.15 (−16.89%) |
|
May 6, 2026
5w ago
|
Press Release
| $3.43 $3.15 | ▼ −8.16% | ▼ −9.29% | $3.15 (−8.16%) |
|
May 5, 2026
5w ago
|
Insider Cluster
| $3.37 $3.26 | ▼ −3.26% | ▼ −5.25% | $3.15 (−6.53%) |
|
Apr 7, 2026
9w ago
|
Insider Cluster
| $3.19 $3.54 | ▲ +10.97% | ▲ +5.64% | $3.15 (−1.25%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $3.17 $3.06 | ▼ −3.47% | ▼ −3.23% | $3.15 (−0.63%) |
|
Mar 17, 2026
12w ago
|
Insider Cluster
| $3.42 $3.17 | ▼ −7.31% | ▼ −4.66% | $3.15 (−7.89%) |
|
Feb 25, 2026
15w ago
|
8-K
| $3.77 $3.64 | ▼ −3.45% | ▼ −2.35% | $3.15 (−16.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access